These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28072764)

  • 1. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
    Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
    Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
    Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
    Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
    J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders.
    Yuo A; Miyazono K; Urabe A; Takaku F
    Jpn J Cancer Res; 1990 Aug; 81(8):820-6. PubMed ID: 2118895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
    Darbaniyan F; Zheng H; Kanagal-Shamanna R; Lockyer P; Montalban-Bravo G; Estecio M; Lu Y; Soltysiak KA; Chien KS; Yang H; Sasaki K; Class C; Ganan-Gomez I; Do KA; Garcia-Manero G; Wei Y
    Exp Hematol; 2022 Nov; 115():44-53. PubMed ID: 36150563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
    Niemeyer CM; Kratz CP
    Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
    Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
    Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
    Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Juvenile myelomonocytic leukaemia: a case series.
    Azma RZ; Zarina AL; Hamidah A; Jamal R; Sharifah NA; Ainoon O; Hamidah NH
    Malays J Pathol; 2009 Dec; 31(2):121-8. PubMed ID: 20514855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
    Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
    J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML).
    Privitera E; Longoni D; Brambillasca F; Biondi A
    Leukemia; 1997 Dec; 11(12):2045-8. PubMed ID: 9447818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
    D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
    Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.